Nippon India Pharma Fund - IDCW - Regular Plan

Other Plans and Options
  • (-7.5%)Nav, as on 06-02-2026

  • Previous Nav

  • Net Change on 06-02-2026

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview IDCW | Regular Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIPPON INDIA PHARMA FUND - IDCW Option -4.33 -3.46 -0.31 22.00 13.94 19.59
BSE Health Care - TRI N/A N/A N/A N/A N/A N/A
BSE SENSEX - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
NIPPON INDIA PHARMA FUND - IDCW Option Jun 05, 2004 -0.31 22.00 13.94 1.82 7,875.40
UTI Healthcare Fund - Regular Plan - IDCW Aug 25, 1999 -1.22 24.04 14.22 2.27 1,055.01
LIC MF Healthcare Fund-Regular Plan-IDCW Feb 28, 2019 -5.09 19.86 10.70 2.45 78.65

Fund Holdings as on 31-January-2026

  • Sun Pharmaceutical Industries Limited

  • Lupin Limited

  • Divi's Laboratories Limited

  • Dr. Reddy's Laboratories Limited

  • Cipla Limited

  • Apollo Hospitals Enterprise Limited

  • MedPlus Health Services Limited

  • Vijaya Diagnostic Centre Limited

  • Ajanta Pharma Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Sai Life Sciences Limited

  • Aurobindo Pharma Limited

  • Abbott India Limited

  • IPCA Laboratories Limited

  • Mankind Pharma Limited

  • JB Chemicals & Pharmaceuticals Limited

  • Thyrocare Technologies Limited

  • Alkem Laboratories Limited

  • Dr. Lal Path Labs Limited

  • Narayana Hrudayalaya Limited

  • Gland Pharma Limited

  • Pfizer Limited

  • Max Healthcare Institute Limited

  • Emcure Pharmaceuticals Limited

  • Suraksha Diagnostic Limited

  • Fortis Healthcare Limited

  • Sanofi India Limited

  • Triparty Repo

  • Sanofi Consumer Healthcare India Limited

  • Syngene International Limited

  • Biocon Limited

  • Akums Drugs and Pharmaceuticals Limited

  • Anthem Biosciences Limited

  • AstraZeneca Pharma India Limited

  • Indoco Remedies Limited

  • Concord Biotech Limited

  • Cash Margin - CCIL

  • Net Current Assets

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Retailing

  • Business Support

  • Miscellaneous

View More

Fund Manager

Most Recent Dividend

  • 06/02/2026

  • 21/02/2025

  • 26/02/2024

  • 28/02/2022

  • 01/03/2021

  • 02/03/2020

  • 05/03/2019

  • 05/03/2018

  • 06/03/2017

  • 08/03/2016

  • 02/02/2015

  • 17/02/2014

  • 14/01/2013

  • 16/03/2012

  • 28/02/2011

  • 31/08/2009

  • 24/03/2008

  • 22/02/2007

  • 19/12/2005

  • Cash

  • Equity

View More

About Nippon India Pharma Fund

Scheme Analysis

Nippon India Pharma Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Nippon India Mutual Fund. It was launched on 05-Jun-2004 and currently has an AUM of ₹7,875.40 crore. Nippon India Pharma Fund is benchmarked against BSE Health Care - TRI as primary index and BSE SENSEX - TRI as secondary index.

The NAV of Nippon India Pharma Fund ended down ₹-8.69(-7.5%)yesterday to ₹107.1439.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The Nippon India Pharma Fund is managed by Sailesh Raj Bhan .

Fund House Contact

4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W) Mumbai - 400 013

022-68087000
022-68087097